Published: 29 April 2021
Author(s): Ayman Elbadawi, Mina Shnoda, Maryrose Laguio-Vila, Mamas A. Mamas, Islam Y. Elgendy
Issue: July 2021
Section: Letter to the Editor

Few therapeutic agents have been proven to be effective in the management of COVID-19 pneumonia in randomized trials, thus the treatment options for this condition remain limited [1,2]. Convalescent plasma is a strategy of infusing specific antibody from the plasma of convalescent patients, and has been previously used to treat other viral diseases. Recent randomized trials have evaluated the efficacy of convalescent plasma with mixed findings [3,4]. In this context, we aimed to conduct a comprehensive meta-analysis of randomized trials to study the efficacy and safety of convalescent plasma in the management of COVID-19 pneumonia on a wide scale of outcomes.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.